Lukas Bubendorf

The paper identifies MTAP deficiency as a biomarker in lung neuroendocrine neoplasms, distinguishing carcinoids from SCLC and LCNEC, and shows it is not caused by 9p21 deletion or promoter hypermethylation.

This study establishes a patient-derived organoid-xenograft platform that models prostate cancer progression, identifies biomarkers, and predicts treatment response.

This study develops an ECM-free culture system for prostate cancer organoids, revealing diverse tumor lineages and identifying in vitro-enriched cell types through single-cell RNA sequencing.

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.